NextCell continuous to strengthen development and collaborative activities
NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations.
NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project, both funded by Vinnova. The work conducted in the projects is a collaborative effort between different types of stakeholders, such as SMEs, big pharma and county councils, all with the common goal of improving the Swedish conditions for innovative cell therapies.
The latest development is that NextCell has just been awarded a Vinnova grant, in order to further develop its IP-strategy, the project is named “Creation of an IP-strategy for an innovative stem cell company”. The 100 000 SEK grant will be used to contract Valea, a highly respected Intellectual Property firm, to assist NextCell in refining the company’s IP-strategy for the future.
“These activities strengthen NextCells network and empowers us to have an impact on the Life Science space in Sweden”, says CEO, Mathias Svahn.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.